SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bacil Pharma - Quaterly Results

02 Nov 2022 Evaluate
The revenue slipped marginally during the September 2022 quarter. A decline of about Rs. 0.00 millions was observed as compared to Rs. 0.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2022 is Rs. -0.04 millions as compared to Net Loss of Rs. -0.77 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 improved to -0.03% as compared to -0.76% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.39 0.17 129.41 1.04 0.23 352.17 0.58 0.74 -21.62
PBIDT -0.03 -0.76 -96.05 0.19 -1.00 -119.00 -38.56 -2.34 1547.86
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.03 -0.76 -96.05 0.19 -1.00 -119.00 -38.56 -2.34 1547.86
Depreciation 0.01 0.01 0.00 0.02 0.02 0.00 0.04 0.05 -20.00
PBT -0.04 -0.77 -94.81 0.17 -1.02 -116.67 -38.60 -2.39 1515.06
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -0.04 -0.77 -94.81 0.17 -1.02 -116.67 -38.60 -2.39 1515.06
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Bacil Pharma Share Price

56.93 0.44 (0.78%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×